Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003356 · ClinicalTrials.gov registry record · Phase 1
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00003356 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 58 participants.
The verdict
NCT00003356, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining rituximab and interleukin-2 intreating patients who have low-grade mantle cell lymphoma or follicular lymphoma.
Interventions
- BIOLOGICAL rituximab
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1997-11 |
| Est. Completion | 2002-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003356
The ClinicalTrials.gov registry entry for NCT00003356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00003356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003356 about?
NCT00003356 is a clinical study titled "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining r...
What is the current status of trial NCT00003356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 1997-11. Estimated completion is 2002-05.
What interventions are being tested in trial NCT00003356?
The interventions under investigation include: rituximab (BIOLOGICAL), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003356?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.